Mankind Pharma IPO: Key Details and Financial Information
Mankind Pharma, a leading pharmaceutical company, recently conducted it's Initial Public Offering (IPO) with the following details:
🔸 Basic Information
- IPO Dates: The IPO was held from 25th to 27th April.
- Price Band: The price range for shares was set at ₹1,026 to ₹1,080.
- Lot Size: Each lot consisted of 13 shares.
- Total Issue Size: The IPO aimed to raise 4,326 Crores.
- Retail Quota: Retail investors were allocated 35% of the shares.
- Date of Allotment: The shares were allotted on 4th May 2023.
- Listing Date: The shares were listed on the stock exchange on 8th May 2023.
🔸 Financial Information
- Earnings per Share (FY'22): Mankind Pharma reported ₹35.78 as earnings per share for the fiscal year 2022.
- Earnings per Share (till Dec 22): The earnings per share for the period until December 2022 was ₹24.87.
- PE Ratio: The price-to-earnings ratio for FY'22 was 30.18x, indicating the valuation of the company's stock relative to its earnings.
- Book Value per Share: The book value per share was ₹153.65, representing the net value of the company per share.
- Price-to-Book Value Ratio: The price-to-book value ratio stood at 7.03x, reflecting the market's valuation of the company relative to its book value.
- Return on Capital Employed (ROCE): Mankind Pharma achieved a ROCE of 16.58%, indicating the company's efficiency in generating profits from its capital investments.
These financial figures provide insights into Mankind Pharma's performance and valuation, assisting investors in making informed decisions about the IPO.
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published here. Any reader taking decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer and also the author does not recommend investing in any offer published on this website.